ENVB
Enveric Biosciences, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-39/100
Last price
1.47
▼ 0.04 (2.65%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.51
Day high
1.53
Day low
1.43
Volume
50.96K
Market cap
$6.58M
P/E (TTM)
—
52W range
1.17 – 13.25
Trailing performance
Returnvs SPY
1W
+1.38%
-0.6%
1M
+5.76%
+4.6%
3M
+3.52%
-1.0%
6M
-24.62%
-42.8%
YTD
-59.50%
-73.8%
1Y
-82.30%
-98.7%
3Y
-99.98%
-182.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on ENVB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
398.04K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 1, 26 | COVENEY KEVIN MICHAEL Chief Financial Officer |
STOCK | 133.33K | $0 | Direct |
| Jun 1, 26 | DEWITT SHEILA Director |
STOCK | 18.52K | $0 | Direct |
| Jun 1, 26 | WEBB MICHAEL D Director |
STOCK | 18.52K | $0 | Direct |
| Jun 1, 26 | PASQUALONE FRANK Director |
STOCK | 18.52K | $0 | Direct |
| Jun 1, 26 | SCHABACKER MARCUS Director |
STOCK | 18.52K | $0 | Direct |
| Jun 1, 26 | KEGLER GEORGE A. JR Director |
STOCK | 18.52K | $0 | Direct |
| Jun 1, 26 | TUCKER JOSEPH EDWARD Chief Executive Officer |
STOCK | 201.12K | $0 | Direct |
| Jun 1, 26 | FACCHINI PETER JAMES Officer |
STOCK | 25.00K | $0 | Direct |
| Dec 23, 25 | DEWITT SHEILA Director |
STOCK | 7.63K | $0 | Direct |
| Dec 23, 25 | WEBB MICHAEL D Director |
STOCK | 7.63K | $0 | Direct |
| Dec 23, 25 | PASQUALONE FRANK Director |
STOCK | 7.63K | $0 | Direct |
| Dec 23, 25 | SCHABACKER MARCUS Director |
STOCK | 7.63K | $0 | Direct |
| Dec 23, 25 | KEGLER GEORGE A. JR Director |
STOCK | 7.63K | $0 | Direct |
| Dec 23, 25 | TUCKER JOSEPH EDWARD Chief Executive Officer |
STOCK | 60.30K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
COVENEY KEVIN MICHAEL |
Chief Financial Officer | 180.75K | Stock Award(Grant) |
DEWITT SHEILA |
Director | 26.31K | Stock Award(Grant) |
FACCHINI PETER JAMES |
Officer | 27.75K | Stock Award(Grant) |
KEGLER GEORGE A. JR |
Director | 26.42K | Stock Award(Grant) |
PASQUALONE FRANK |
Director | 26.42K | Stock Award(Grant) |
SCHABACKER MARCUS |
Director | 26.42K | Stock Award(Grant) |
TUCKER JOSEPH EDWARD |
Chief Executive Officer | 271.48K | Stock Award(Grant) |
WEBB MICHAEL D |
Director | 26.42K | Stock Award(Grant) |
Fundamentals
Market cap$6.58M
Enterprise value$-1.72M
Revenue (TTM)—
Gross profit—
EBITDA$-8.57M
Net income$-12.09M
EPS (TTM)$-13.01
Free cash flow$-5.20M
Total cash$8.30M
Total debt$0
Book value / share$2.05
Shares outstanding4.48M
Float4.34M
Short % of float0.52%
Dividend yield0.00%
Beta (5Y)1.18
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.04
PEG ratio—
Price / sales—
Price / book0.72
EV / revenue—
EV / EBITDA0.20
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-170.04%
Return on assets-87.34%
Debt / equity—
Current ratio10.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Gross profit | — | — | — | — | $0 | — |
| Research & development | $2.78M | $2.84M | $7.25M | $8.03M | — | -2.1% |
| Selling, general & admin | $5.79M | $6.45M | $10.70M | $11.61M | — | -10.2% |
| Total operating expense | $8.77M | $9.63M | $18.30M | $19.96M | — | -8.9% |
| Operating income | -$8.77M | -$9.63M | -$18.30M | -$19.96M | — | +8.9% |
| Net interest income | -$106 | $219 | $3.71K | -$5.25K | — | -148.4% |
| Pre-tax income | -$8.77M | -$9.57M | -$17.26M | -$19.96M | — | +8.3% |
| Tax provision | $0 | $8.93K | $28.91K | -$1.49M | — | -100.0% |
| Net income | -$8.77M | -$9.57M | -$17.31M | -$18.50M | — | +8.4% |
| Net income to common | -$12.13M | -$9.57M | -$17.46M | -$18.80M | — | -26.7% |
| Basic EPS | -36.24 | -228.48 | -1,455.48 | -195.00 | — | +84.1% |
| Diluted EPS | -36.24 | -228.48 | -1,455.48 | -195.00 | — | +84.1% |
| EBIT | -$8.77M | -$9.63M | -$18.30M | -$19.95M | — | +8.9% |
| EBITDA | -$8.57M | -$9.29M | -$17.89M | -$19.52M | — | +7.8% |
| Basic shares | 334.72K | 502.90K | 143.94K | 96.40K | — | -33.4% |
| Diluted shares | 334.72K | 502.90K | 143.94K | 96.40K | — | -33.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.68M | $2.24M | $2.29M | $17.72M | — | +108.7% |
| Cash & short-term investments | $4.68M | $2.24M | $2.29M | $17.72M | — | +108.7% |
| Total current assets | $4.94M | $2.73M | $3.58M | $18.43M | — | +80.5% |
| Property, plant & equipment | $159.23K | $305.78K | $507.38K | $741.30K | — | -47.9% |
| Goodwill & intangibles | $0 | $42.18K | $210.93K | $379.69K | — | -100.0% |
| Total assets | $5.10M | $3.08M | $4.30M | $19.55M | — | +65.3% |
| Total current liabilities | $918.40K | $1.49M | $2.34M | $4.00M | — | -38.4% |
| Total debt | — | — | $0 | $63.82K | $176.30K | — |
| Total liabilities | $918.40K | $1.49M | $2.34M | $4.00M | — | -38.4% |
| Retained earnings | -$114.85M | -$106.07M | -$96.50M | -$79.21M | — | -8.3% |
| Shareholder equity | $4.18M | $1.59M | $1.96M | $14.67M | — | +162.3% |
| Working capital | $4.02M | $1.24M | $1.24M | $14.44M | — | +222.8% |
| Net tangible assets | $4.18M | $1.55M | $1.75M | $14.29M | — | +169.4% |
| Shares issued | 1.06M | 678.00K | 182.62K | 138.55K | — | +56.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$8.77M | -$9.57M | -$17.29M | -$18.47M | — | +8.4% |
| Depreciation & amortisation | $200.86K | $337.49K | $408.03K | $435.20K | — | -40.5% |
| Stock-based compensation | $827.32K | $1.56M | $2.15M | $2.62M | — | -47.0% |
| Change in working capital | -$295.94K | -$423.24K | -$174.75K | -$217.66K | — | +30.1% |
| Operating cash flow | -$8.14M | -$7.73M | -$14.09M | -$17.15M | — | -5.4% |
| Capital expenditure | — | — | -$5.18K | -$584.16K | -$864.72K | — |
| Investing cash flow | — | $0 | $11.67K | -$584.16K | $2.19M | — |
| Share buybacks | — | $0 | -$1.05M | $0 | — | — |
| Financing cash flow | $10.58M | $7.67M | -$1.34M | $18.18M | — | +37.9% |
| Free cash flow | -$8.14M | -$7.73M | -$14.10M | -$17.73M | — | -5.4% |
| End cash position | $4.68M | $2.24M | $2.29M | $17.72M | — | +108.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $1.36M | $345.97K | $372.18K | $402.42K | $1.26M | — | +291.7% |
| Selling, general & admin | $1.64M | $1.25M | $1.78M | $1.43M | $1.22M | — | +30.8% |
| Total operating expense | $3.03M | $1.63M | $2.19M | $1.87M | $2.52M | — | +85.4% |
| Operating income | -$3.03M | -$1.63M | -$2.19M | -$1.87M | -$2.52M | — | -85.4% |
| Net interest income | -$292 | -$303 | -$250 | $274 | -$132 | — | +3.6% |
| Pre-tax income | -$3.03M | -$1.63M | -$2.19M | -$1.87M | -$2.52M | — | -85.4% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$3.03M | -$1.63M | -$2.19M | -$1.87M | -$2.52M | — | -85.4% |
| Net income to common | -$3.03M | -$1.63M | -$4.04M | -$3.39M | -$2.52M | — | -85.4% |
| Basic EPS | -0.76 | -1.08 | — | -10.81 | -11.65 | -14.58 | +29.6% |
| Diluted EPS | -0.76 | -1.08 | — | -10.81 | -11.65 | -14.58 | +29.6% |
| EBIT | -$3.03M | -$1.63M | -$2.19M | -$1.87M | -$2.52M | — | -85.4% |
| EBITDA | -$2.99M | -$1.60M | -$2.15M | -$1.83M | -$2.48M | — | -87.4% |
| Basic shares | 3.99M | 1.51M | — | 313.24K | 216.31K | 149.81K | +164.0% |
| Diluted shares | 3.99M | 1.51M | — | 313.24K | 216.31K | 149.81K | +164.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.30M | $4.91M | $4.68M | $3.76M | $2.85M | — | +69.0% |
| Cash & short-term investments | $8.30M | $4.91M | $4.68M | $3.76M | $2.85M | — | +69.0% |
| Total current assets | $8.79M | $5.38M | $4.94M | $4.17M | $3.31M | — | +63.6% |
| Property, plant & equipment | $81.93K | $119.93K | $159.23K | $196.52K | $241.08K | — | -31.7% |
| Goodwill & intangibles | — | — | $0 | $0 | $0 | $0 | — |
| Total assets | $8.94M | $5.52M | $5.10M | $4.36M | $3.55M | — | +62.0% |
| Total current liabilities | $861.48K | $460.68K | $918.40K | $905.88K | $1.36M | — | +87.0% |
| Total liabilities | $861.48K | $460.68K | $918.40K | $905.88K | $1.36M | — | +87.0% |
| Retained earnings | -$119.51M | -$116.48M | -$114.85M | -$112.65M | -$110.78M | — | -2.6% |
| Shareholder equity | $8.08M | $5.06M | $4.18M | $3.46M | $2.18M | — | +59.7% |
| Working capital | $7.93M | $4.91M | $4.02M | $3.26M | $1.94M | — | +61.4% |
| Net tangible assets | $8.08M | $5.06M | $4.18M | $3.46M | $2.18M | — | +59.7% |
| Shares issued | 3.94M | 1.89M | 1.06M | 518.30K | 3.03M | — | +108.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$3.03M | -$1.63M | -$2.19M | -$1.87M | -$2.52M | -85.4% |
| Depreciation & amortisation | $36.83K | $37.24K | $39.48K | $40.37K | $39.98K | -1.1% |
| Stock-based compensation | $125.11K | $88.67K | $240.23K | $186.98K | $206.26K | +41.1% |
| Change in working capital | $421.25K | -$768.88K | $100.14K | -$299.95K | $382.80K | +154.8% |
| Operating cash flow | -$2.44M | -$2.26M | -$1.78M | -$2.07M | -$1.89M | -8.3% |
| Financing cash flow | $5.84M | $2.50M | $2.69M | $2.99M | $449.10K | +133.5% |
| Free cash flow | -$2.44M | -$2.26M | -$1.78M | -$2.07M | -$1.89M | -8.3% |
| End cash position | $8.30M | $4.91M | $4.68M | $3.76M | $2.85M | +69.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2024 | -2.76 | -2.03 | +26.4% |
| Sep 2024 | — | -43.20 | — |
| Jun 2024 | -99.00 | -45.00 | +54.6% |
| Mar 2024 | -139.50 | -109.80 | +21.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders8.89%
Held by institutions12.02%
Institutions holding26
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.49
-1.57% from price
SMA 20
1.50
-2.03% from price
SMA 50
1.48
-0.40% from price
SMA 100
1.56
-5.81% from price
SMA 200
2.27
-35.21% from price
EMA 12
1.49
-1.34% from price
EMA 26
1.48
-0.94% from price
EMA 50
1.51
-2.53% from price
RSI (14)
48.5
Neutral
MACD (12,26,9)
0.01
Hist -0.01
ATR (14)
0.09
6.39% of price
Realised vol 30D
44.2%
Annualised
Bollinger upper
1.60
20, 2σ
Bollinger lower
1.40
20, 2σ
50 / 200 cross
Death
1.48 vs 2.27
Trend bias
Below 200
-35.21%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.33
More volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
44.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-88.2%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.09
6.39% of price
Beta (reported)
1.18
5Y monthly, from filing
Short interest
Shares short
22.87K
Prior 17.26K
Change vs prior
+32.5%
Shorts adding
% of float
0.52%
Normal
% of shares out
0.51%
Against total outstanding
Days to cover
0.2
Liquid
Float
4.34M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 6, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 30, 24 | HC Wainwright & Co. | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend dateApr 23, 2008
Next pay dateNov 25, 2019
Last split1:12
Split dateOct 28, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-06-09
Offering Registrations
S-8 · 2026-06-01
Corporate Changes & Voting Matters
8-K · 2026-05-29
Periodic Financial Reports
10-Q · 2026-05-15
Additional Forms
D · 2026-05-04
Corporate Changes & Voting Matters
8-K · 2026-04-30
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-04-28
Headlines
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Business Wire · 22d ago
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
Business Wire · 36d ago
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Business Wire · 54d ago
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
Business Wire · 63d ago
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Business Wire · 71d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.